PHS 2024-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications
Funding organization: National Institutes of Health (NIH)
Total funding support for Phase I awards may not exceed $306,872
Total funding support for Phase II awards may not exceed $2,045,816
Award periods normally may not exceed 1 year for Phase I and 2 years for Phase II
To invite eligible United States small businesses to submit STTR grant applications
To support research and development that has strong potential for commercialization
United States small business concerns (SBCs)
NIH awarding components
Only United States small business concerns (SBCs) are eligible to apply
SBCs must be organized for profit and have a place of business located in the United States
SBCs must be more than 50% owned and controlled by U.S. citizens or permanent resident aliens
Eligible organizations must be located in the United States
Non-domestic (non-U.S.) entities are not eligible to apply
Projects must not propose clinical trials
Applications must demonstrate potential for commercialization
Total funding support for Phase I and Phase II awards is specified
No cost sharing is required
Applications are due by 5:00 PM local time of applicant organization
Key deadlines include September 5, 2025, for the latest application submission
SBCs must meet performance benchmarks related to Phase I to Phase II transition rates
Applications must follow the SBIR/STTR (B) Instructions in the How to Apply – Application Guide
Specific forms and documentation as outlined in the application guide must be submitted
Applications will be evaluated based on scientific and technical merit
Review criteria include significance, innovation, approach, and environment
Applications will undergo peer review and be assigned an overall impact score
Second level of review by the appropriate national Advisory Council or Board
Relevance of the proposed project to program priorities will be considered
Availability of funds will also influence funding decisions
Applications must not propose clinical trials
SBCs must secure substantial independent third-party investor funds
Non-domestic entities and components are not eligible to apply
SBCs must meet specific performance benchmarks to maintain eligibility
Projects that align with NIH's mission to improve health and save lives are prioritized
SBCs with a strong commercialization plan may have a competitive advantage
Demonstrating strong potential for commercialization is crucial
Adhering to application guidelines and deadlines is essential
Submitting applications that do not comply with the guidelines
Failing to secure necessary registrations in advance
Engage with program officials early in the application process
Ensure all required registrations are completed before submission
Highlight unique aspects of the proposed project that align with NIH priorities
Demonstrate the ability to secure third-party funding